Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Calliditas Therapeutics Suisse SA
Condition: Squamous Cell Carcinoma of Head and Neck
NCT05323656
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.